

line 13, please insert -- SEQ ID NO: 1-- after “-NH₂”;
line 15, please insert -- SEQ ID NO: 8-- after “-NH₂”; and
line 17, please insert -- SEQ ID NO: 36-- after “-NH₂”.

At page 18, line 8, please insert -- SEQ ID NO: 37-- after “-NH₂”.

At page 19, line 25, please insert -- SEQ ID NO: 13-- after “-NH₂”; and
line 26, please insert -- SEQ ID NO: 14-- after “-NH₂”.

At page 20, line 26, please insert -- SEQ ID NO: 15-- after “-NH₂”.

REMARKS

Applicants submit a Sequence Listing for the nucleotide sequences disclosed in the specification, in compliance with the requirements for patent applications containing nucleotide sequences and/or amino acid sequence disclosures. 37 C.F.R. §§ 1.821-1.825. Additionally, Applicants have amended the specification to include the appropriate SEQ ID NOS following each sequence.

CONCLUSION

Applicants respectfully submit that the present application complies with 37 C.F.R. §§ 1.821-1.825. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicant

c/o Mintz, Levin

One Financial Center

Boston, MA 02111

Telephone (617) 542 6000

Fax (617) 542 2241

Date: September 25, 2000

TRADOC:1377132.1(T\$L_01!.DOC)